Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.
van Opijnen MP, Tesileanu CMS, Dirven L, van der Meer PB, Wijnenga MMJ, Vincent AJPE, Broekman MLD, Dubbink HJ, Kros JM, van Duinen SG, Smits M, French PJ, van den Bent MJ, Taphoorn MJB, Koekkoek JAF. van Opijnen MP, et al. Among authors: taphoorn mjb. Neuro Oncol. 2023 Apr 6;25(4):701-709. doi: 10.1093/neuonc/noac197. Neuro Oncol. 2023. PMID: 35972438 Free PMC article.
PCV chemotherapy for recurrent glioblastoma multiforme.
Kappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, Zonnenberg BA, Sneeuw KC, Heimans JJ. Kappelle AC, et al. Neurology. 2001 Jan 9;56(1):118-20. doi: 10.1212/wnl.56.1.118. Neurology. 2001. PMID: 11148250
Temozolomide chemotherapy in recurrent oligodendroglioma.
van den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJ, Kros JM, Eskens FA, Carpentier AF. van den Bent MJ, et al. Neurology. 2001 Jul 24;57(2):340-2. doi: 10.1212/wnl.57.2.340. Neurology. 2001. PMID: 11468326
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B. van den Bent MJ, et al. Ann Oncol. 2003 Apr;14(4):599-602. doi: 10.1093/annonc/mdg157. Ann Oncol. 2003. PMID: 12649108 Free article. Clinical Trial.
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht ChJ, Allgeier A, Gorlia T; European Organization for Research and Treatment of Cancer Brain Tumor Group. van den Bent MJ, et al. J Clin Oncol. 2003 Jul 1;21(13):2525-8. doi: 10.1200/JCO.2003.12.015. J Clin Oncol. 2003. PMID: 12829671 Clinical Trial.
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A, Kros JM, Stege EB, Enting RH, Allgeier A, van Heuvel I, van den Bent MJ. Triebels VH, et al. Neurology. 2004 Sep 14;63(5):904-6. doi: 10.1212/01.wnl.0000137049.65631.db. Neurology. 2004. PMID: 15365146 Clinical Trial.
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A; European Organisation for Research and Treatment of Cancer Brain Tumour Group; EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group. Taphoorn MJ, et al. Lancet Oncol. 2005 Dec;6(12):937-44. doi: 10.1016/S1470-2045(05)70432-0. Lancet Oncol. 2005. PMID: 16321761 Clinical Trial.
312 results